Immunic, Inc.
IMUX
Positions held
Your positionsIMUX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $103.15M | Enterprise value | -$51.38M | Trailing P/E | — | Forward P/E | -3.11 |
| PEG | — | Price / book | 0.81 | Beta | 1.45 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -138.2% | ROA | -66.8% | Debt / equity | 0.00 |
| Current ratio | 5.05 | Free cash flow | -$51.41M | Analyst recommendation | strong_buy | Mean target | $43.09 |
| 52w high | $17.43 | 52w low | $5.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$34.1M | -$32.6M | -$19.3M | -$25.6M | -$26.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$35.3M | -$33.2M | -$23.3M | -$26.0M | -$27.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$97.2M | -$101M | -$93.6M | -$120M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$103M | -$98.1M | -$99.2M | -$86.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Immunic to present four vidofludimus calcium abstracts at MSToronto2026
2026-09-02 · Immunic to host virtual relapsing MS R&D Day on September 9
2026-09-02 · Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
2026-09-01 · Immunic appoints Chitrang Davé as chief data and digital officer
2026-09-01 · Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
2026-08-13 · Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
2026-08-11 · Immunic advances MS drug toward key Phase 3 data, expects results by year-end
2026-08-11 · Immunic: Q2 Earnings Snapshot
2026-08-11 · Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-10 · Immunic appoints Elena Ridloff to board of directors
2026-08-10 · Immunic Appoints Elena Ridloff to Board of Directors
Price (daily)
Full chart · RSI · MACD · patterns